A Mab A Case Study In Bioprocess Development

From Flask to Drum: A Case Study in Monoclonal Antibody (mAb) Bioprocess Development

In the world of modern medicine, few innovations have been as transformative as the monoclonal antibody (mAb). From treating cancer to managing autoimmune disorders, these Y-shaped proteins have become the cornerstone of biotherapeutics.

1. Early clone selection dictates success – The top 0.1% of clones (A-Mab-7B12) outperformed the average by 300%.
2. DoE is non-negotiable – From media to elution to formulation, statistical design saved 18 months of trial-and-error.
3. Sensitive molecules need gentle chromatography – Low-pH tolerance cannot be assumed; arginine was a lifesaver.
4. High concentration is a separate challenge – Viscosity and particles require orthogonal solutions.
5. Scale-up always surprises – kLa, mixing time, and shear stress change non-linearly.

4. Analytical & Formulation Challenges

• Aggregation: Identified low pH during Protein A elution as cause. Mitigation: reduced hold time, added 200 mM arginine in elution buffer.
• Charge variants: CEX resolved acidic variants; later mapped to deamidation (Asn-55). Controlled by limiting bioreactor pH drift.
• Forced degradation studies: mAb stable for 24 months at 2–8°C; no significant fragmentation.

3.2 Protein A Affinity Chromatography – The Workhorse

The initial Protein A step used MabSelect SuRe™ resin. Loading at 30 g A Mab/L resin captured >99% of product, but elution at pH 3.5 caused significant aggregation (from 1.5% to 7%). A Mab A Case Study In Bioprocess Development

The design space was defined such that any combination within ranges (e.g., Protein A elution pH 3.6–4.0, polishing flow rate 150–250 cm/h) yielded CQA compliance. From Flask to Drum: A Case Study in